Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSmallwood, Natasha-
dc.contributor.authorMann, Jennifer-
dc.contributor.authorGuo, Hui-
dc.contributor.authorGoh, Nicole SL-
dc.identifier.citationThe American journal of hospice & palliative care 2021; 38(2): 154-160-
dc.description.abstractFibrotic interstitial lung diseases (f-ILDs) are often progressive and incurable. As patients experience significant symptoms and have a poor prognosis, early palliative care referral is recommended. To examine the care delivered to patients with f-ILD during the terminal hospital admission and the past 2 years of life. A retrospective audit was performed for consecutive patients who died from f-ILD at 2 Australian teaching hospitals between January 1, 2012, and December 31, 2016. Of 67 patients, 44 (66%) had idiopathic pulmonary fibrosis. Median age was 78 years. Median respiratory function: forced expiratory volume in 1 second 69.0% predicted (interquartile range [IQR]: 58.0%-77.0%), forced vital capacity 64.0% predicted (IQR = 46.8%-74.3%), and diffusing capacity of carbon monoxide 36.0% predicted (IQR = 31.0%-44.0%). In the 2 years prior to the terminal admission, 38 (57%) patients reported severe breathlessness and 17 (25%) used opioids for symptom relief. Twenty-four (36%) patients received specialist palliative care (SPC) and 11 (16%) completed advance care planning. During the terminal admission, 10 (15%) patients were admitted directly under SPC. A further 33 (49%) patients were referred to SPC, on average 1 day prior to death. Sixty-three (94%) patients received opioids and 49 (73%) received benzodiazepines for symptom management. Median starting and final opioid doses were 10 and 23 mg oral morphine equivalent/24 hours, respectively. Opioids were commenced on average 2 (IQR 1-3) days prior to death. Although most patients were identified as actively dying in the final admission, referral to SPC and use of palliative medications occurred late. Additionally, few patients accessed symptom palliation earlier in their illness.-
dc.subjectadvance care planning-
dc.subjectidiopathic pulmonary fibrosis-
dc.subjectinterstitial lung disease-
dc.subjectpalliative care-
dc.titlePatients With Fibrotic Interstitial Lung Disease Receive Supportive and Palliative Care Just Prior to Death.-
dc.typeJournal Article-
dc.identifier.journaltitleThe American journal of hospice & palliative care-
dc.identifier.affiliationDepartment of Medicine (Royal Melbourne Hospital), University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australiaen
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Mar 3, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.